Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

45.58 +1.52 (+3.46%)
Streaming Delayed Price Updated: 2:57 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) sent the company a warning letter regarding “false or... 
Via StockStory
BigBear.ai, Tesla, Hims & Hers, Rocket Lab, Warner Bros Discovery: Stocks Making The Biggest Moves Today
Via Stocktwits
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days. 
Via Benzinga
FDA Slams Hims & Hers With A Warning Letter. Investors Slam Hims Stock.
The company is best-known for its compounded weight-loss drugs. But those could be in trouble. 
Via Investor's Business Daily
Hims & Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened
Via Stocktwits
Huge News for Hims & Hers Stock
Testosterone could be a huge growth market for Hims & Hers. 
Via The Motley Fool
Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q2 Earnings?
The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 55.7%, hitting $54 per share. This run-up might have investors contemplating their... 
Via StockStory
Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks
FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA... 
Via Benzinga
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the afternoon session after the stock extended its positive momentum as the company announced its expansion into the... 
Via StockStory
Topics Artificial Intelligence
Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts
Via Stocktwits
3 Cash-Producing Stocks on Our Watchlist
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions. 
Via StockStory
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone... 
Via StockStory
Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone
According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday. 
Via Stocktwits
Why Hims & Hers Health (HIMS) Stock Is Trading Up Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market. 
Via StockStory
Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone
The company is making a move into a highly anticipated area and partnering with a privately held pharmaceutical company. 
Via Investor's Business Daily
Topics ETFs
Hims & Hers Bets On Hormonal Health To Revive Investor Confidence
Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows. 
Via Benzinga
Hims Launches New Category in Men’s Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments
From Hims & Hers
Via Business Wire
Hims & Hers To Launch Low Testosterone Treatments for Men As Weight-Loss Drug Sales Slow
The telehealth company is expanding into hormonal health with plans to eventually add therapies for women in perimenopause and menopause. 
Via Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why Hims & Hers Health (HIMS) Stock Is Up Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.9% in the morning session after it continued a rally from the previous day fueled by strong revenue guidance and supportive analyst... 
Via StockStory
Topics ETFs Economy
4 Top Stocks to Buy in September
Here are four stocks to buy now that could offer investors upside in both the short and long term. 
Via The Motley Fool
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
HIMS & HERS ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire
Hims & Hers, which boasts a $9.7 billion market cap, is up 170% over the past year, though it's pulled back nearly 25% this past month. 
Via Benzinga
Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers
Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses. 
Via Benzinga
Topics ETFs
HIMS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the August 25th Deadline for the Hims Lawsuit and Urges Investors to Contact The Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
From Faruqi & Faruqi, LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.